Clearside Biomedical, Inc. (CLSD) SEC Filing 10-Q Quarterly report for the period ending Sunday, March 31, 2019

Clearside Biomedical, Inc.

CIK: 1539029 Ticker: CLSD

Exhibit 99.1



Clearside Biomedical Announces First Quarter 2019 Financial Results and Provides Corporate Update

- Scientific Presentations Support Broad Applicability of Clearside Delivery Platform -

- XIPERE under review for October 19, 2019 PDUFA Date -

- Management to Host Webcast and Conference Call Today at 8:30 A.M. ET -


ALPHARETTA, Ga., May 8, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the first quarter of 2019 and provided a corporate update.


“Clearside has a compelling opportunity to leverage our innovative, non-surgical suprachoroidal space (SCS) delivery platform to make a difference for patients with sight-threatening diseases in the U.S. and around the world,” said George Lasezkay, Pharm.D., J.D., Clearside’s Interim Chief Executive Officer. “We believe our proprietary approach and strong intellectual property in the suprachoroidal space are broadly applicable across a range of serious ophthalmic diseases.”


Dr. Lasezkay continued, “We are validating our platform with the potential approval of our first product candidate, XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection for the treatment of macular edema associated with uveitis, a condition that currently has no approved therapies. Uveitis is a leading cause of vision impairment and blindness in the developed world, and treating the associated macular edema is particularly important as it is an underserved patient population often affecting younger people and can result in numerous years of lost visual function.”


“We have a highly experienced team that developed XIPERE, submitted our New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), and is now focused on achieving the successful approval and launch of our first commercial product. We are also committed to maximizing our SCS injection platform to expand our product pipeline and create future value through select strategic partnerships. As indicated in recent medical meeting presentations, the potential of our SCS injection platform includes small molecule therapeutics and may extend to gene-based therapies for inherited retinal diseases,” concluded Dr. Lasezkay.




The following information was filed by Clearside Biomedical, Inc. (CLSD) on Wednesday, May 8, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Clearside Biomedical, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Clearside Biomedical, Inc..


Assess how Clearside Biomedical, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Clearside Biomedical, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors




Learn More
Bullish Bearish Neutral
Filter by Sentiment:
Filter by Category:
Filter by Subcategory:
Cash Flow
Inside Clearside Biomedical, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Balance Sheets
Balance Sheets (Parenthetical)
Statement Of Stockholders' Equity
Statements Of Cash Flows
Statements Of Operations
Accrued Liabilities
Accrued Liabilities (Tables)
Accrued Liabilities - Schedule Of Accrued Liabilities (Details)
Available-For-Sale Investments
Available-For-Sale Investments (Tables)
Available-For-Sale Investments - Summary Of Company's Available-For-Sale Investments (Details)
Collaboration Agreements
Collaboration Agreements - Additional Information (Detail)
Commitment And Contingencies
Commitment And Contingencies (Tables)
Commitment And Contingencies - Additional Information (Details)
Commitment And Contingencies - Operating Leases Included On The Balance Sheet (Details)
Commitment And Contingencies - Total Future Undiscounted Minimum Lease Payments (Details)
Common Stock
Common Stock - Additional Information (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Additional Information (Details)
Fair Value Measurements - Summary Of Assets Measured At Fair Value (Details)
Long-Term Debt
Long-Term Debt (Tables)
Long-Term Debt - Additional Information (Details)
Long-Term Debt - Scheduled Payments For The Second Amended And Restated Loan And Security Agreement (Details)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Potential Common Stock Equivalents Excluded From Computation Of Diluted Net Loss Per Share (Details)
Property And Equipment, Net
Property And Equipment, Net (Tables)
Property And Equipment, Net - Schedule Of Property And Equipment, Net (Details)
Share-Based Compensation
Share-Based Compensation (Tables)
Share-Based Compensation - Additional Information (Details)
Share-Based Compensation - Summary Of Activity Related To Stock Options (Details)
Share-Based Compensation - Summary Of Share-Based Compensation Expense (Details)
Significant Accounting Policies
Significant Accounting Policies (Policies)
Significant Accounting Policies - Additional Information (Details)
Stock Purchase Warrants
Stock Purchase Warrants - Additional Information (Details)
The Company
The Company - Additional Information (Details)

Material Contracts, Statements, Certifications & more

Clearside Biomedical, Inc. provided additional information to their SEC Filing as exhibits

Ticker: CLSD
CIK: 1539029
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-19-018552
Submitted to the SEC: Fri May 10 2019 12:16:21 PM EST
Accepted by the SEC: Fri May 10 2019
Period: Sunday, March 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: